[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acne-scars\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acne-scars":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,79,112,138,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100639796","safety-and-efficacy-evaluation-of-the-radiofrequency-therapeutic-device-for-the-treatment-of-atrophic-acne-scars-100639796",false,"NCT07620769","Safety and Efficacy Evaluation of the Radiofrequency Therapeutic Device for the Treatment of Atrophic Acne Scars","A Prospective, Multicenter, Randomized, Parallel-Controlled, Blinded-Assessment, Non-Inferiority Clinical Trial to Evaluate the Safety and Effectiveness of a Radiofrequency Therapeutic Device for the Treatment of Atrophic Acne Scars","Inclusion Criteria:\n\n1. Participants aged 18 to 65 years at the time of written informed consent.\n2. Participants with Fitzpatrick skin types II to V.\n3. Participants with facial atrophic acne scars and an ECCA score ≥60 as assessed by the investigator.\n4. Participants who are able to understand the purpose and procedures of the study, voluntarily agree to participate, and provide written informed consent.\n\nExclusion Criteria:\n\n1. Participants with a history of facial surgery or cosmetic surgical procedures, or those planning to undergo cosmetic surgical treatment during the study period, which in the investigator's judgment may increase treatment risk or affect efficacy evaluation, including any of the following:\n2. Participants with active or progressive skin diseases in the treatment area, or skin diseases associated with the Koebner phenomenon, such as eczema, psoriasis vulgaris, lichen planus, or vitiligo, which in the investigator's judgment may affect treatment or evaluation.\n3. Participants with open wounds, malignant or unspecified skin tumors, precancerous lesions, or viral, bacterial, or fungal infections in the treatment area, including herpes simplex, verruca vulgaris, verruca plana, cutaneous tuberculosis, or mycobacterial infections.\n4. Participants with scars, tattoos, piercings, excessive hair, or other conditions in the treatment area that, in the investigator's judgment, may interfere with treatment or evaluation.\n5. Participants with impaired skin barrier function in the treatment area that, in the investigator's judgment, may increase treatment risk or affect efficacy evaluation.\n6. Participants with a history of excessive sun exposure within 1 month prior to screening that, in the investigator's judgment, may increase treatment risk or affect efficacy evaluation.\n7. Participants with known hypersensitivity or allergy to lidocaine, other local anesthetics, or any device or medication components used in this study.\n8. Participants with severe hepatic or renal dysfunction, serious disease of other major organs, or uncontrolled diabetes mellitus.\n9. Participants with abnormal coagulation function during screening, use of medications affecting platelet or coagulation function, or platelet count below the lower limit of normal.\n10. Participants with active autoimmune disease or a history of autoimmune disease, including systemic lupus erythematosus, rheumatoid arthritis, scleroderma, or dermatomyositis.\n11. Participants with a history of keloid formation.\n12. Participants diagnosed with psychiatric disorders or active anxiety or depression that may impair the ability to understand or comply with study requirements.\n13. Participants with metallic implants such as cardiac pacemakers or implantable cardioverter-defibrillators.\n14. Participants planning pregnancy during the study period or unwilling to use medically acceptable contraception methods.\n15. Participants who are pregnant or breastfeeding.\n16. Participants who participated in another clinical trial involving a drug and\u002For medical device within 1 month prior to enrollment.\n17. Participants considered unsuitable for participation by the investigator for any other reason.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},252,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this clinical trial is to evaluate the safety and effectiveness of a radiofrequency treatment device for the treatment of atrophic acne scars.\n\nThis is a prospective, multicenter, randomized, parallel-controlled, blinded-assessment, non-inferiority trial design.\n\nThe study aims to evaluate the effectiveness and safety of the radiofrequency therapeutic device manufactured by Sponsor for the treatment of atrophic acne scars, in comparison with the control device, the radiofrequency therapeutic device.\n\nParticipants will receive treatment sessions using either the investigational device or the control device, undergo follow-up evaluations after treatment to assess efficacy and safety outcomes.\n\nThe primary endpoint is Improvement in atrophic acne scars measured by the ECCA score compared with baseline, assessed 12 weeks after the final treatment.\n\nThe secondary efficacy endpoints include Global Aesthetic Improvement Scale (GAIS), Study Participant Satisfaction Assessment, Pain Score, Changes in skin characteristics compared with baseline Safety evaluations include Adverse events (AEs), Serious adverse events (SAEs)",[28,29,30,31],"Acne Scars","Acne Scars - Atrophic","Acne Scar","Acne Scarring",[33,34,35,36],"acne scar","atrophic acne scar","radiofreqency device","Radiofrequency Therapeutic Device","NOT_YET_RECRUITING","2026-05-29",{"date":40,"type":41},"2026-06-02","ACTUAL",{"date":43,"type":22},"2026-06",{"date":45,"type":22},"2027-10",{"name":47,"class":48},"CLASSYS Inc.","INDUSTRY",4,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100597468","evaluation-of-juline-tm-for-the-treatment-of-atrophic-facial-acne-scars-100597468","NCT07058883","Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars","Prospective, Randomized, Placebo-Controlled, Multicenter Clinical Trial Evaluating the Efficacy and Safety of Juläine (Polylactic Acid) in the Treatment of Facial Acne Scars","Inclusion Criteria:\n\n* Age 18 years or older\n* Presence of moderate to severe atrophic facial acne scars\n* Immune-competent adult\n* Willing and able to comply with study procedures and follow-up visits\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Active acne, infection, or chronic skin disease in the treatment area\n* Known allergy or hypersensitivity to any component of Juläine\n* History of keloid formation or hypertrophic scarring\n* Current anticoagulant therapy or bleeding disorder\n* Pregnant or breastfeeding\n* Previous aesthetic treatment in the same area within the past 6 months\n* Participation in another interventional clinical trial within 30 days before enrollment",{"count":58,"type":22},55,[25],"This study aims to evaluate the effectiveness and safety of Juläine, an injectable medical device made of polylactic acid, for treating facial acne scars. Participants with atrophic acne scars will be randomly assigned to receive either Juläine or a placebo (saline). The treatment will consist of three injection sessions over two months, followed by a 12-month observation period. The study will measure changes in scar severity and skin quality over time using clinical assessments and imaging tools. The study is being conducted at multiple dermatology clinics in Poland and is approved by a local ethics committee.",[28],[63,64,65,66,67],"polylactic acid","facial scars","acne","aesthetic","injectable device","RECRUITING","2026-03-16",{"date":71,"type":41},"2026-03-18",{"date":73,"type":41},"2026-03-13",{"date":75,"type":22},"2027-03",{"name":77,"class":48},"Nordberg Medical AB",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":111},"100607543","comparative-real-world-study-on-ablative-fractional-co-laser-vs-prp-with-microneedling-for-acne-scar-treatment-100607543","NCT07189923","Comparative Real-world Study on Ablative Fractional CO₂ Laser vs PRP With Microneedling for Acne Scar Treatment.","Efficacy and Safety of Ablative Fractional CO2 Laser and Platelet-rich Plasma (PRP) With Microneedling for Treatment of Acne Scars: a Real-world Comparative Study","Inclusion Criteria:\n\n* Adult patients (age \\>18 years)\n* Both male and female sex\n* Patients with grade 2 to grade 4 acne scars, classified on the basis of Goodman's Qualitative classification.\n* Patient with equal Goodman's Qualitative scores on both halves of the face.\n* No active acne lesions.\n* Patients with atrophic scars only.\n\nExclusion Criteria:\n\n* Positive history of keloidal tendency.\n* Positive history of bleeding or platelet disorder.\n* Positive history of major surgery in past 6 months.\n* Presence of any acute infection on face like, herpes, folliculitis.\n* Patients of HIV, HBsAg, or any chronic illness.\n* Pregnancy",{"count":87,"type":22},116,[25],"Road traffic accidents (RTAs) remain a major public health concern worldwide and in Bangladesh, contributing significantly to injury, disability, and premature death. In resource limited settings like Bangladesh, it is crucial to understand the factors that influence survival following an RTA in order to develop effective prevention strategies and improve patient outcomes. Therefore, this study aims to determine the 30 day survival rate and identify predictors of survival among adult RTA victims treated at a tertiary care hospital in Bangladesh. The observational study will be carried out at Emergency and casualty department of Dhaka Medical College Hospital (DMCH) between October 2025 and March 2026. A total of 204 adults (≥18 years) presenting to the hospital's Casualty Department with RTA related injuries will be included. Informed written consent will be obtained from each patient or their legal guardian prior to enrollment. Data will be collected through structured face to face interviews, review of hospital records, and follow up on the 30th day of accident. The follow-up will be conducted either in person or by telephone. Variables will include patient demographics, accident circumstances, admission characteristics, injury pattern and severity, pre-hospital care, clinical condition at admission, hospital management provided, and treatment outcome. All data will be analyzed using SPSS version 25.0. Kaplan-Meier analysis will estimate survival probabilities, while Cox proportional hazards regression will be used to identify independent predictors of mortality. The findings of this study are expected to generate context-specific, evidence-based insights for strengthening trauma care protocols, gap related to emergency handling of the RTA patients, enhancing pre-hospital emergency services, and informing policy decisions aimed at reducing preventable RTA-related mortality and morbidity in Bangladesh.",[28,91,92],"Ablative Fractional CO₂ Laser Therapy","Platelet-rich Plasma (PRP)",[28,94,95,96,97,98,99,100],"Ablative fractional CO₂ laser therapy","Platelet-rich plasma (PRP)","Microneedling","Efficacy","Safety","Bangladesh","Goodman and Baron scale","2025-12-02",{"date":103,"type":41},"2025-12-03",{"date":105,"type":22},"2025-12-01",{"date":107,"type":22},"2026-11-30",{"name":109,"class":110},"Dr. Sirajul Islam Medical College","OTHER",1,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":111},"100604598","efficacy-of-combined-fractional-erglass-and-thulium-lasers-versus-microneedling-for-atrophic-acne-scars-100604598","NCT07151599","Efficacy of Combined Fractional Er:Glass and Thulium Lasers Versus Microneedling for Atrophic Acne Scars","Randomized Controlled Trial Comparing Fractional Erbium:Glass (1540-1550 nm) and Thulium (1927 nm) Lasers Versus Microneedling for the Treatment of Atrophic Acne Scars","Inclusion Criteria:\n\n* Fitzpatrick skin phototypes I to VI\n* Presence of atrophic acne scars on the face\n\nExclusion Criteria:\n\n* Decompensated systemic diseases\n* Any active infection (e.g., viral such as herpes, bacterial, or fungal)\n* Pregnant or breastfeeding women\n* Presence of hypertrophic or keloid scars\n* Current use of anticoagulant or antiplatelet medications\n* History of hemophilia or coagulation disorders\n* Current use of anti-inflammatory drugs or corticosteroids\n* Use of retinoids, including isotretinoin, within the past 6 months\n* Exposure to sunlight within the past 15 days\n* Undergoing any aesthetic facial treatment or having undergone scar treatments in the facial region within 180 days prior to study initiation\n* Presence of active acne (occasional isolated lesions will not be considered exclusion criteria)","45 Years",{"count":121,"type":22},84,[25],"The purpose of this study is to compare two treatments for acne scars on the face. The study will test whether fractional lasers (Erbium:Glass and Thulium) lead to better improvement in acne scars than microneedling.",[28],[126,127,96,128,28],"Fractionated Erbium Glass Laser","Fractionated Thulium Laser","Percutaneous Induction of Collagen","2025-11-24",{"date":131,"type":41},"2025-11-26",{"date":133,"type":41},"2025-10-16",{"date":135,"type":22},"2026-07",{"name":137,"class":110},"University of Nove de Julho",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100608885","phase-3-a-study-to-assess-the-safety-and-effectiveness-of-elapr002f-injectable-gel-in-adult-participants-with-atrophic-acne-scars-100608885","NCT07207369","A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars","A Multicenter, Cohort-design, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars","Inclusion Criteria:\n\n* Participants in general good health, and seeking improvement of atrophic acne scars.\n* Moderate to severe atrophic acne scarring (Grade 4 or 5 on the Allergan Acne Scar Improvement Scale \\[ASIS\\]) on each cheek based on evaluating investigator (EI) live assessment (both cheeks must qualify but do not need to have the same score) at the first Screening Visit.\n* At least 5 rolling or boxcar-type acne scars in total within the predefined 4 cm × 4 cm assessment field of either cheek in areas of otherwise normal healthy skin, as assessed by the treating investigator (TI).\n\nExclusion Criteria:\n\n* The participant has clinically significant acne on the face.\n* Current cutaneous or mucosal inflammatory or infectious processes other than acne (eg, herpes), rosacea, abscess, an unhealed wound, or a cancerous or precancerous lesion, on the face.\n* The participant presents with predominantly ice pick scars.\n* History of keloid scar formation, hypertrophic scarring, and\u002For post inflammatory hyperpigmentation or hypopigmentation.","22 Years",{"count":147,"type":22},395,[149],"PHASE3","Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment\u002Fself consciousness. ELAPR002f provides an immediate space-occupying effect for filling in the scar tissue. The purpose of this study is to assess how safe and effective ELAPR002f injectable gel is on adult participants with atrophic acne scars.\n\nELAPR002f injectable gel is an investigational device being developed for the treatment of facial atrophic acne scars. There are 2 cohorts in this study. In Cohort 1, all participants will receive ELAPR002f injectable gel. In Cohort 2, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to the saline active control group. Around 395 adult participants with moderate to severe atrophic acne scarring on both cheeks will be screened in the study in approximately 25 sites in the United States.\n\nParticipants will receive 3 treatments over 2 months of intradermal injections of either ELAPR002f injectable gel or saline active control and will be followed for up to an additional 12 months.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[28],[28,153],"ELAPR002f injectable gel","2025-11-20",{"date":129,"type":41},{"date":157,"type":41},"2025-10-24",{"date":159,"type":22},"2029-11",{"name":161,"class":48},"AbbVie",10,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":170,"maxAge":119,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":4},"100600243","efficacy-of-stromal-vascular-fraction-on-acne-scar-correction-100600243","NCT07094958","Efficacy of Stromal Vascular Fraction on Acne Scar Correction","Efficacy of Intradermal Stromal Vascular Fraction Injection in the Treatment of Atrophic Acne Scar","Inclusion Criteria:\n\n* Age between 19 and 45 years\n* Presence of bilateral atrophic acne scars (boxcar, rolling, or icepick types) on the face\n* Willingness to undergo fat harvesting procedure\n* Ability to comply with study visits and follow-up\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Active acne lesions on the treatment area\n* History of keloid or hypertrophic scarring\n* Prior treatment for acne scars (e.g., laser, filler, microneedling) within the past 6 months\n* History of systemic immunosuppressive therapy within the past 3 months\n* Pregnant or breastfeeding women\n* Any systemic disease that may interfere with wound healing or safety assessment (e.g., uncontrolled diabetes, collagen vascular disease)","19 Years",{"count":172,"type":22},16,[25],"This study aims to evaluate the efficacy and safety of intradermal injection of autologous stromal vascular fraction (SVF) in the treatment of atrophic acne scars. SVF is a heterogeneous cell population derived from adipose tissue, containing various regenerative and immunomodulatory cells, including mesenchymal stem cells, endothelial progenitor cells, and pericytes.\n\nIn this prospective, randomized, split-face clinical trial, participants with atrophic acne scars will receive SVF injections on one side of the face and normal saline (NS) injections on the contralateral side as a control. Clinical efficacy will be assessed through blinded scar counts, digital imaging, and histological evaluations including epidermal and dermal regenerative markers. The study is designed to investigate whether SVF provides superior clinical improvement compared to placebo.",[28,29],"2025-07-29",{"date":178,"type":41},"2025-07-31",{"date":180,"type":22},"2025-07",{"date":135,"type":22},{"name":183,"class":110},"Seoul National University Hospital"]